Firm gains rights in Taiwan, Hong Kong, Singapore, and Malaysia, while Solasia hangs on to China and Japan.
Kyowa Hakko Kirin has obtained an exclusive right to market and sell Solasia Pharma’s antiemetic in Taiwan, Hong Kong, Singapore, and Malaysia. Sancuso is an extended-release transdermal system delivering the antiemetic granisetron, a 5-HT3 receptor antagonist.
The therapy was approved by the FDA in September 2008 for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to five consecutive days. ProStrakan launched Sancuso in the U.S. in the fourth quarter of 2008. In May 2008, Solasia acquired the exclusive right to Sancuso from ProStrakan for Japan, China, and other territories in Asia. Solasia retains full rights in Japan and China where it is currently conducting Sancuso clinical trials.
According to the terms of the arrangement between Solasia and Kyowa Hakko Kirin, Solasia will receive an up-front fee as well as regulatory- and sales-related milestones. Kyowa Hakko Kirin will be responsible for all commercialization activities in Taiwan, Hong Kong, Singapore, and Malaysia. Solasia will supply the product to Kyowa Hakko Kirin in these territories.
